Drug Manufacturing

Star Therapeutics’ von Willebrand disease therapy gains FDA fast track status

Star Therapeutics' investigational monoclonal antibody, VGA039, has gained fast track designation from the US Food and Drug Administration (FDA) for the treatment of von Willebrand disease (VWD).

Brii Biosciences acquires BRII-179 assets from VBI Vaccines

Brii Biosciences (Brii Bio) has entered into an agreement to acquire the intellectual property and other assets related to the Hepatitis B immunotherapeutic candidate, BRII-179 from VBI Vaccines (VBI) and its creditor K2 VBI Equity Trust and K2 HealthVentures.

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

WuXi Biologics (WuXi Bio) and Sino Biopharm have entered into a service agreement for the discovery of a monoclonal antibody (mAb) for a target that is not disclosed.

Axcelead DDP and Astellas partner for targeted protein degrader discovery

Axcelead Drug Discovery Partners (Axcelead DDP) has signed a drug discovery service agreement with Astellas Pharma for new candidate compounds for targeted protein degraders.

Bio-Thera and Tabuk partner for Stelara biosimilar in Saudi Arabia

Bio-Thera Solutions has entered into a partnership with Astra Industrial Group subsidiary, Tabuk Pharmaceutical Manufacturing Company, to bring BAT2206, Jansen's Stelara (ustekinumab) biosimilar, to the Saudi Arabian market.

Basilea receives additional funding from CARB-X to advance antibiotic candidate

Basilea Pharmaceutica has received an additional $7.3m from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance its antibiotic candidate, BAL2420, towards first-in-human clinical trials expected by mid-2026.

WuXi Biologics and Hangzhou DAC sign ADC agreement

WuXi Biologics, in partnership with Hangzhou DAC Biotechnology, has entered into a research service agreement with Aadi Bioscience for antibody-drug conjugates (ADCs).

Assembly Bio and Gilead collaborate to advance antiviral therapeutic programmes

Assembly Biosciences has received an investment from Gilead Sciences, comprising a $20.1m equity investment and $10m in accelerated funding, to propel the clinical development of new antiviral therapies targeting herpesviruses, hepatitis B virus (HBV), and hepatitis D virus (HDV).

Agios announces EC’s positive decision for sickle cell disease therapy designation

The European Commission (EC) has adopted a positive decision for designating Agios Pharmaceuticals’ oral, small molecule pyruvate kinase (PK) activator, mitapivat, as an orphan medicinal product (OMP) for treating sickle cell disease.